Pharmacyte BiotechPMCB
13F holders, Q1 2024 (March 31)29holders
2famous investors
$2.37avg. 13F price*
At the end of Q1 2024, 29 institutions reported holding Pharmacyte Biotech Inc. (PMCB) in their 13F filings. The largest holders were K2 Principal Fund, L.P. ($776K), Geode Capital Management, LLC ($475K) and Vanguard Group Inc. ($414K). 2 famous investors held it, including Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio) and Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Pharmacyte Biotech Inc.
- CUSIP
- 71715X203
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $17 |
| Exits | 4 | $246K |
Ownership 29 holders
| K2 Principal Fund, L.P. | 0.40% | Add +7.5% | 327,503 | $776K |
| Geode Capital Management, LLC | 0.00% | Reduce -7.1% | 200,281 | $475K |
| Vanguard Group Inc. | 0.00% | Add +1.9% | 174,602 | $414K |
| Equitec Proprietary Markets, LLC | 0.35% | No change | 82,727 | $196K |
| Renaissance Technologies | 0.00% | Add +15.0% | 43,800 | $104K |
| Susquehanna International Group, LLP | 0.00% | Add +87.0% | 41,188 | $98K |
| Dimensional Fund Advisors LP | 0.00% | Reduce -16.2% | 24,563 | $58K |
| Schonfeld Strategic Advisors LLC | 0.00% | Add +1.3% | 23,500 | $56K |
| BlackRock Inc. | 0.00% | Reduce -26.6% | 21,104 | $50K |
| Northern Trust Corp. | 0.00% | Reduce -0.3% | 19,229 | $46K |
| Citadel Advisors | 0.00% | Reduce -70.1% | 8,561 | $20K |
| Acadian Asset Management LLC | 0.00% | Reduce -25.1% | 3,589 | $8K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +72.2% | 3,229 | $8K |
| Osaic Holdings, Inc. | 0.00% | Add +0.5% | 1,767 | $4K |
| Cwm, LLC | 0.00% | No change | 954 | $2K |
| Aspire Private Capital, LLC | 0.00% | No change | 800 | $2K |
| Covestor Ltd | 0.00% | No change | 226 | $1K |
| Kelly Financial Services LLC | 0.00% | No change | 234 | $555 |
| Wells Fargo & Company | 0.00% | No change | 55 | $130 |
| Bank of America Corp. | 0.00% | Reduce -12.9% | 54 | $128 |
| Private Wealth Management Group, LLC | 0.00% | No change | 42 | $100 |
| JPMorgan Chase & Co. | 0.00% | Add +50.0% | 18 | $43 |
| Highlander Capital Management, LLC | 0.00% | No change | 14 | $33 |
| Sachetta, LLC | 0.00% | No change | 14 | $31 |
| UBS Group AG | 0.00% | Reduce -30.8% | 9 | $21 |
| Bfsg, LLC | 0.00% | New | 7 | $17 |
| Morgan Stanley | 0.00% | Reduce -25.0% | 3 | $9 |
| NewEdge Advisors, LLC | 0.00% | No change | 3 | $7 |
| Royal Bank of Canada | 0.00% | Reduce -41.1% | 156 | $0 |
"% of holder's portfolio" is PMCB's weight in each manager's 13F, not the share of Pharmacyte Biotech Inc. the manager owns.